Bacteremia due to Mycobacterium massiliense in a patient with chronic myelogenous leukemia: case report

Hamamoto, Takaaki; Yûki, Atsushi; Naoi, Kenji; Kawakami, Saki; Banba, Yukiharu; Yamamura, Takeshi; Hikota, Reina; Watanabe, Junichi; Kimura, Fumihiko; Nakanaga, Kazue; Hoshino, Yoshihiko; Ishii, Norihisa; Shimazaki, Hideyuki; Nakanishi, Kuniaki; Tamai, Susumu

doi:10.1016/j.diagmicrobio.2012.06.009

Cited by 6 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This bacterium was also the source of a lethal case of sepsis in Italy (12) and has been found in cystic fibrosis patients in France (13). Several cases of bacteremia and cutaneous pulmonary infections have also been reported in Japan (14)(15)(16)(17).…”

mentioning

confidence: 99%

Discrimination of Mycobacterium abscessus subsp. massiliense from Mycobacterium abscessus subsp. abscessus in Clinical Isolates by Multiplex PCR

et al. 2014

Self Cite

View full text Add to dashboard Cite

The rapidly growing mycobacterium M. abscessus sensu lato is the causative agent of emerging pulmonary and skin diseases and of infections following cosmetic surgery and postsurgical procedures. M. abscessus sensu lato can be divided into at least three subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii. Clinical isolates of rapidly growing mycobacteria were previously identified as M. abscessus by DNA-DNA hybridization. More than 30% of these 117 clinical isolates were differentiated as M. abscessus subsp. massiliense using combinations of multilocus genotyping analyses. A much more cost-effective technique to distinguish M. abscessus subsp. massiliense from M. abscessus subsp. abscessus, a multiplex PCR assay, was developed using the whole-genome sequence of M. abscessus subsp. massiliense JCM15300 as a reference. Several primer sets were designed for single PCR to discriminate between the strains based on amplicons of different sizes. Two of these single-PCR target sites were chosen for development of the multiplex PCR assay. Multiplex PCR was successful in distinguishing clinical isolates of M. abscessus subsp. massiliense from samples previously identified as M. abscessus. This approach, which spans whole-genome sequencing and clinical diagnosis, will facilitate the acquisition of more-precise information about bacterial genomes, aid in the choice of more relevant therapies, and promote the advancement of novel discrimination and differential diagnostic assays. bolletii, and that a new subspecies, M. abscessus subsp. abscessus, should be designated (9). However, a recent whole-genome study strongly supported the hypothesis that the species can be divided into at least three subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii (10). M. abscessus subsp. massiliense was initially isolated from the sputum of a patient with pneumonia in France in 2004 (5). In 2005, an outbreak of M. abscessus subsp. massiliense infection was linked to intramuscular injections of an antimicrobial agent in South Korea (11). This bacterium was also the source of a lethal case of sepsis in Italy (12) and has been found in cystic fibrosis patients in France (13). Several cases of bacteremia and cutaneous pulmonary infections have also been reported in Japan (14-17).A novel approach is required to differentiate M. abscessus subsp. massiliense from M. abscessus subsp. abscessus and M. abscessus subsp. bolletii because conventional methods such as biochemical assays and 16S rRNA genotyping cannot make the discrimination. Moreover, the clinical profile of M. abscessus subsp. massiliense is different from those of M. abscessus subsp. abscessus and M. abscessus subsp. bolletii. In particular, antibiotic treatment with clarithromycin is more effective against M. abscessus subsp. massiliense lung infections, with resistance developing more readily in cases of M. abscessus subsp. abscessus lung disease. Therefore, differentiating ...

show abstract

mentioning

confidence: 99%

Discrimination of Mycobacterium abscessus subsp. massiliense from Mycobacterium abscessus subsp. abscessus in Clinical Isolates by Multiplex PCR

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…These findings suggest that bacteremia is a prominent feature of M massiliense infection in transplant recipients. In other settings, bacteremia due to M massiliense has also been reported in patients with hematological malignancies receiving chemotherapy 20,21 . Therefore, once M massiliense has been detected in samples from the lung or soft tissue, blood culture should also be performed, especially in highly immunosuppressed patients.…”

Section: Discussionmentioning

confidence: 99%

“…In regard to the susceptibility profile, M massiliense is in general highly susceptible to macrolides (clarithromycin). Therefore, early identification of the isolate and initiation of macrolide‐based antimicrobial treatment could contribute to a favorable outcome of M massiliense infection 5,9,21,23 . Therefore, a recently published management guideline of M abscessus complex recommends the combination of macrolides (azithromycin) and amikacin as the initial intensive treatment for pulmonary M massiliense infection for 6‐8 weeks in pediatric patients with cystic fibrosis 24 .…”

Section: Discussionmentioning

confidence: 99%

Disseminated Mycobacterium massiliense infection in a patient with myelodysplastic syndrome undergoing allogeneic bone marrow transplantation

Toyama

Mori

Kato

et al. 2020

Transplant Infectious Dis

Self Cite

View full text Add to dashboard Cite

Nontuberculous mycobacteria are ubiquitous in water and soil, and the subset of rapidly growing mycobacteria species can cause severe infections in immunocompromised patients. Solid organ or hematopoietic stem cell transplantation (HSCT) recipients are known to be susceptible to infection by nontuberculous mycobacteria.The nontuberculous mycobacteria species Mycobacterium massiliense (M massiliense) has been classified as a rapidly growing mycobacteria and recognized as a pathogen causing lung and soft tissue infections in humans. However, there have been only a few reported cases of M massiliense infection after solid organ transplantation and HSCT. We herein report another case of M massiliense infection after allogeneic HSCT, which manifested as soft tissue infection, lung infection, and bacteremia.

show abstract

“…However, M. massiliense sepsis was fatal in the first two reported cases (9,10). Although M. massiliense has been isolated from respiratory specimens from a few bacteremia cases (10,11), M. massiliense is a frequent colonizer of immunosuppressed patients (7,14,21). Virulence causing fatal outcomes in cases of bacteremia has not yet been resolved.…”

mentioning

confidence: 99%

“…In the present case, NTM lung infection was diagnosed first in a patient without underlying lung disease, and bacteremia was diagnosed 1 month later. Immunosuppression is a major risk factor for both lung infection and disseminated NTM infection (9)(10)(11). Cell-mediated immunity is a major defense mechanism against NTM infections, in which gamma interferon (IFN-␥)-activated macrophages play a key role (15).…”

mentioning

confidence: 99%

Mycobacterium massiliense Bacteremia as a Consequence of M. massiliense Pneumonia in a Patient with Acute Lymphoblastic Leukemia

et al. 2014

View full text Add to dashboard Cite

show abstract

Bacteremia due to Mycobacterium massiliense in a patient with chronic myelogenous leukemia: case report

Cited by 6 publications

References 8 publications

Discrimination of Mycobacterium abscessus subsp. massiliense from Mycobacterium abscessus subsp. abscessus in Clinical Isolates by Multiplex PCR

Discrimination of Mycobacterium abscessus subsp. massiliense from Mycobacterium abscessus subsp. abscessus in Clinical Isolates by Multiplex PCR

Disseminated Mycobacterium massiliense infection in a patient with myelodysplastic syndrome undergoing allogeneic bone marrow transplantation

Mycobacterium massiliense Bacteremia as a Consequence of M. massiliense Pneumonia in a Patient with Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About